{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262943446855296.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/gut.2005.089722"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/gut.2005.089722"}}],"dc:title":[{"@value":"Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n                    <jats:bold>Objective:</jats:bold>\n                    In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon α-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:</jats:bold>\n                    Multivariate analyses were performed using available data from 518 patients treated with peginterferon α-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20 000 copies/ml.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Results:</jats:bold>\n                    In logistic regression analyses across all treatment arms, peginterferon α-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon α-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon α-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon α-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon α-2a with or without lamivudine therapy.\n                  </jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:</jats:bold>\n                    Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon α-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon α-2a with or without lamivudine.\n                  </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380294643784549901","@type":"Researcher","foaf:name":[{"@value":"F Bonino"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855304","@type":"Researcher","foaf:name":[{"@value":"P Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855309","@type":"Researcher","foaf:name":[{"@value":"G K K Lau"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855296","@type":"Researcher","foaf:name":[{"@value":"S Hadziyannis"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855305","@type":"Researcher","foaf:name":[{"@value":"R Jin"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855310","@type":"Researcher","foaf:name":[{"@value":"T Piratvisuth"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855297","@type":"Researcher","foaf:name":[{"@value":"G Germanidis"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855303","@type":"Researcher","foaf:name":[{"@value":"C Yurdaydin"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855302","@type":"Researcher","foaf:name":[{"@value":"M Diago"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855298","@type":"Researcher","foaf:name":[{"@value":"S Gurel"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855308","@type":"Researcher","foaf:name":[{"@value":"M-Y Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855306","@type":"Researcher","foaf:name":[{"@value":"M R Brunetto"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855307","@type":"Researcher","foaf:name":[{"@value":"P Farci"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855299","@type":"Researcher","foaf:name":[{"@value":"M Popescu"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943446855301","@type":"Researcher","foaf:name":[{"@value":"P McCloud"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00175749"},{"@type":"EISSN","@value":"14683288"}],"prism:publicationName":[{"@value":"Gut"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2006-11-24","prism:volume":"56","prism:number":"5","prism:startingPage":"699","prism:endingPage":"705"},"reviewed":"false","url":[{"@id":"https://syndication.highwire.org/content/doi/10.1136/gut.2005.089722"}],"createdAt":"2006-11-24","modifiedAt":"2025-11-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232550879360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643784549888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664425007744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772498432","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化；HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"en","@value":"Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFNα-2a treatment after surgery for hepatocellular carcinoma: a case report"},{"@value":"症例報告 肝発癌後にPeg-IFNα-2a投与によりHBs抗原陰性化 : HBs抗体陽性化が得られたB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク カンハツガン ゴ ニ Peg-IFNa-2a トウヨ ニ ヨリ HBs コウゲン インセイカ : HBs コウタイ ヨウセイカ ガ エラレタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390865806744558592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Chronic Hepatitis B in Which HBs Antigen Seroclearance Was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up"},{"@value":"A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/gut.2005.089722"},{"@type":"CROSSREF","@value":"10.2957/kanzo.57.666_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0263844_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.3643-24_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.3390/ijms19071940_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"},{"@type":"CROSSREF","@value":"10.1016/j.virusres.2012.10.027_references_DOI_GEerUS75W0GsqJ589ZzWRBJhJjj"}]}